Summer Project 2

A

Summer Project Report

On

Submitted in partial fulfillment of the requirement for Master of Business

Administration (MBA Pharmaceuticals)

Submitted to

Kadi Sarva Vishwavidyalaya

Sector-15

Gandhinagar-382015

May-June-2010

Submitted By Project Guide

Hardik V. Patel MBA (PHARMA)

“Prelaunch Survey of Ramipril

And

Ramipril Hydrochlorothiazide Combination”

CERTIFICATE FROM THE INSTITUTE

This is to certify that the contents of this report entitled “Prelaunch Survey of

Ramipril and Ramipril Hydrochlorothiazide Combination” by Hardik V Patel,

Roll No. 52, MBA (Pharma) submitted to Kadi Sarva Vishwavidyalaya,

Gandhinagar, for the partial fulfillment of award of Master of Business

Administration is original research work carried out by him.

This report, to the best of my knowledge, has not been submitted either partly

or fully to any other University or Institute for award of any degree or diploma.

Date: 15/07/2010 Dr. G.B.Shah

Place: Gandhinagar Principal,

KBIPER

MY ENTIRE WORK OF PROJECT

HAS BEEN DEDICATED TO GOD,

MY LOVING PARENTS, MY

ELDER BROTHER & MY

FRIENDS WHO ALWAYS

SUPPORTED ME….

DECLARATION

I, Mr. Hardik V. Patel, student of the MBA (Pharma) affiliated to Kadi Sarva

Vishwavidyalaya, Gandhinagar hereby declare that this project is a result of

culmination of my sincere efforts.

I declare that this submitted work is done solely by me and to the best of my

knowledge. I have tried at my level best to collect precise detail to provide useful

information to the company.

I also declare that all the information collected from various sources has been

duly acknowledged in this project report.

Hardik V. Patel

MBA (Pharma)

Kadi Sarva Vishwavidyalaya

ACKNOWLEDGEMENT

Here, I take this opportunity to humbly express my gratitude to all those

concerned with my project entitled “Prelaunch survey of Ramipril and Ramipril

Hydrochlorothiazide Combination”. I would like to share the success of my project

amongst the person who has directly and indirectly helped me to complete this

project.

In providing concrete shape of my project, there are numerous people who

have taken part. I take this opportunity to express my deep sense of gratitude and

hearty thanks to my Professor Mrs. Mallika Babu for her efforts to get training in the

company. I am hearty thankful to her for providing me her valuable suggestions and

remarks to complete this project. Her extensive knowledge of subject and the way,

she imparted the same to me has enabled me to develop the project cohesive manner.

We are highly obliged to Mr. Maulesh Shah

. For allocating such an interesting project. In spite of being very busy, they

were ready to help me whenever required. The whole staff of Kamron Laboratories

Ltd. was co-operative and I am thankful for all the support they extended to me.

A special thanks to my friends Mr. Sumit Tiwari and Mr. Yashrajsinh Rathod

for his continuous support and guidance made my work very easy.

I would like to express my heartiest thanks to my family, parents and brother

to extend their help as and when required. I would like to thank my friends- Arshad,

Gunjan and Ronak. Without their support this would not be possible.

My guide at the institute shared his expertise knowledge, so I sincerely thank

to Principal Dr. G.B.Shah and Dr. Srikalp Deshpande.

Hardik V. Patel

PREFACE

Summer training is an essential part of curriculum of MBA, affiliated to Kadi

Sarva Vishwavidyalaya, and it is compulsory for every student.

Management colleges provide their students theoretical knowledge but it

remains incomplete without practical knowledge. Moreover students of MBA are

required to gather maximum practical exposure towards corporate world. This

experience provides the best of knowledge for any MBA students which can’t be

attained in class-room teaching.

Through this project report work I can better understand the different aspects

like research design, measurement and scaling techniques, questionnaire and its

design, data collection, analysis and interpretation. Through this report I can

understand business research methodology in practical term.

The major emphasize of my work was to analyze the current market scenario

of Ramipril and Ramipril hydrochlorothiazide.

The working experience with Kamrom laboratories ltd., Kalol, Gandhinagar,

was very exciting and it has created a long lasting impression in my mind. This

project gave me immense opportunities to upgrade my knowledge related to

marketing field and also gave me a chance to learn and understand the strategies to be

kept in mind while launching a new product.

EXECUTIVE SUMMERY

Kamron Laboratories Ltd., has been set up in 1990 for manufacture of

pharmaceutical formulations in dosage forms like Tablets, Capsules, Liquid Orals,

Dry Syrups, Eye Drops and Injections. They have divided their products in three

different groups as follows.1) Panchratna Brands 2) Platinum Blue Group: Platinum

Green 3) Titanium Brands”. I had done my summer project under titanium brands.

The objective of my project was to do a survey of molecules Ramipril and

Ramipril Hydrochlorothiazide combination in various areas of Ahmedabad to find out

the market potential of given molecules.

In first section of my report I had given brief information about

pharmaceutical industry and in second section I had given brief information of

Kamron laboratories ltd.

In the main part of my project, I analyzed various parameters based on the

survey conducted of 150 chemists of mentioned areas. The main potential seller of

Ramipril and Ramipril Hydrochlorothiazide are Sanofi Aventis (Cardace), Micro

Cardicare (Hopace), Alkem (Race), Cipla (Ramipres), Lupin (Ramistar), Macleods

(Macpril) etc.

At the end of the project, I had given my own findings and few of suggestions

to guide the launch of these two molecules.

TABLE OF CONTENT

Sr no. Content Page no 1 Introduction of Indian pharmaceutical industry

Advantage India

The growth scenario

Cardiovascular drug market

Major players in Indian market

2 Company profile

About Kamron

Core values of Kamron laboratories ltd

Vision statement of Kamron

Mission statement – Kamron

Facilities

Research & development

Quality assurance

International certifications

Brand management team

Product list

3 Data analysis

Objectives

Research methodology:

Working area:

Research design:

Plan of work:

About the molecules

Data interpretation

Findings

Suggestions

Limitation of survey

References

Appendix

LIST OF GRAPH

Sr no. Graph Content Page no

1 Sale of number of strips per week of different companies

2 Percentage of total sale

3 Sale Of Strip Of Ramipril And Ramipril Hydrochlorothiazide

(Strength wise)

4 Sale Of Strip Of Ramipril And Ramipril Hydrochlorothiazide

(Dosage form wise)

5 Unit percentage value

6 Total sale(Regular Vs New Prescription)

LIST OF TABLE

Sr no. Table Content Page no

1 India’s domestic pharmaceutical market

2 Brand classification of Kamron

3 Available brands in the market

4 Sale of number of strips per week of different companies

5 Percentage of total sale

6 Sale of strip of Ramipril and Ramipril

hydrochlorothiazide(strength wise)

7 Sale of strip of Ramipril and Ramipril hydrochlorothiazide

(dosage form wise)

8 Unit percentage value

9 Analysis of regular sale and new prescription.

PROJECT REPORT

Introduction of Indian Pharmaceutical industry

“The Indian pharmaceutical industry is a success story providing

employment for millions and ensuring that essential drugs at affordable

prices are available to the vast population of this sub-continent.”

-Richard Gerster

“The future depends on what we do in the present”

India is the world’s fourth largest producer of pharmaceuticals by volume,

accounting for around 8% of global production. In value terms, production accounts

for around 1.5% of the world total. The Indian pharmaceutical industry directly

employs around 500,000 people and is highly fragmented having more then 20000

companies. While there are around 270 large R&D based pharmaceutical companies

in India, including multinationals, government-owned and private companies, there

are also around 5,600 smaller licensed generics manufacturers.

The Indian Pharmaceutical industry currently tops the chart amongst India's

science-based industries with wide ranging capabilities in the complex field of drug

manufacture and technology. A highly organized sector, the Indian pharmaceutical

industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent

annually. It ranks very high amongst all the third world countries, in terms of

technology, quality and the vast range of medicines that are manufactured.

Indian Pharmaceutical Industry ranks fourth in the world, pertaining to the

volume of sales. The estimated worth of the Indian Pharmaceutical Industry is

Rs.55,454 Crores. The growth rate of the industry is about 13% per year. Almost most

70% of the domestic demand for bulk drugs is catered by the Indian Pharma Industry.

The Pharma Industry in India produces around 20% to 24% of the global

Generic drugs. The Indian Pharmaceutical Industry is one of the biggest producers of

the Active Pharmaceutical Ingredients (API) in the international arena. The Indian

Pharma sector leads the science-based industries in the country. Around 40% of the

total pharmaceutical produce is exported. 55% of the total exports constitute of

formulations and the other 45%comprises of bulk drugs.

The Indian Pharma Industry includes small scaled, medium scaled, large

scaled players, which totals nearly 300 different companies. As per the present growth

rate, the Indian Pharma Industry is expected to be a US$ 20 billion industry by the

year 2015. The Indian Pharmaceutical sector is also expected to be among the Top

Ten Pharma based markets in the world in the next ten years. The sales of the Indian

Pharma Industry would worth US$ 43 billion within the next decade. The

multinational companies, investing in research and development in India may save up

to 30% to 50% of the expenses incurred.

The top revenue-generating therapeutic groups in the Rs 55,454 crore

domestic markets are Anti-infective, Gaestro, Cardiac, Respiratory, Pain management

and Vitamins. Incidentally, the vitamins, minerals and nutrients segment is the only

area (among the ones tracked by ORG-IMS) where five of the top 10 players are

foreign multinational firms.While the market leader is the Indian subsidiary of

Germany’s Merck Ltd, the other foreign MNCs among the top 10 are

GlaxoSmithKline (GSK), Pfizer, Novartis and Abbott.

Indian companies among the top 10 are Cipla, Ranbaxy, Wockhardt, Piramal

Healthcare and Zydus Cadila.

Bussiness Standard

The domestic market of Indian pharmaceutical industry is likely to register

12%-13% growth in 2009, only marginally lower than the earlier projections of 15%

as an impact of macroeconomic conditions, according to ORG IMS Research. The

impact of macroeconomic factors is much less on the Indian companies compared to

the global peers. In the next 4-5 years, this industry is expected to continue to grow at

more than 10% to touch the $30 billion mark by 2020. In the long term, the domestic

consumption is expected to keep growing at a healthy pace, because currently India’s

healthcare spending is only 5.6% of the country’s gross domestic product (GDP),

which is among the lowest globally.

Highly Fragmented Pharmaceutical Industry

The domestic pharmaceutical market is quite fragmented with the top five

companies commanding only 22% market share. Cipla Ltd has become the largest and

the fastest growing company among the top five companies, outclassing Ranbaxy

Laboratories Ltd. Even the top 20 companies have a total market share of about 57%

only in contrast to the global drug market dominated by the 10 largest companies that

account for about 40% of global sales. The Indian Pharmaceutical sector is highly

fragmented with more than 20,000 registered units. It has expanded drastically in the

last two decades. The leading 250 pharmaceutical companies control 70% of the

market with market leader holding nearly 7% of the market share. It is an extremely

fragmented market with severe price competition and government price control.

There are about 250 large units and about 8000 Small Scale Units, which form

the core of the pharmaceutical industry in India. These units produce the complete

range of pharmaceutical formulations, i.e., medicines ready for consumption by

patients and about 350 bulk drugs, i.e., chemicals having therapeutic value and used

for production of pharmaceutical formulations

India’s Domestic Pharmaceutical Market

Company Size ($ Billion) Market Share (%) Growth Rate (%)

Total Pharma Market 6.9 100.0 9.9

Cipla 0.36 5.3 13.4

Ranbaxy 0.34 5.0 11.5

Glaxo Smithkline 0.29 4.3 -1.2

Piramal Healthcare 0.27 3.9 11.7

Zydus Cadila 0.24 3.6 6.8

Total of Top 5 1.53 22.1

SOURCE : ORG MIS

[Table no-1]

ADVANTAGE INDIA

Competent workforce: India has a pool of personnel with high managerial and

technical competence as also skilled workforce. It has an educated work force and

English is commonly used. Professional services are easily available.

Cost-effective chemical synthesis: its track record of development, particularly in

the area of improved cost-beneficial chemical synthesis for various drug molecules is

excellent. It provides a wide variety of bulk drugs and exports sophisticated bulk

drugs.

Legal & Financial Framework: India has a 60 year old democracy and hence has a

solid legal framework and strong financial markets. There is already an established

international industry and business community.

Globalization: The country is committed to a free market economy and globalization.

Above all, it has a 70 million middle class market, which is continuously growing.

Consolidation: For the first time in many years, the international pharmaceutical

industry is finding great opportunities in India. The process of consolidation, which

has become a generalized phenomenon in the world pharmaceutical industry, has

started taking place in India.

THE GROWTH SCENARIO

Indian contract research industry growing at 40-50 per cent

The Indian contract research Industry has grown tremendously over the past

few years. It has witnessed the emergence of several CROs in the area of drug

discovery & development over the last decade.

India to capture US$ 250-300 million or 10 per cent of global clinical trials by

2010.

India is emerging as a favored global destination for global drug development

companies. Recent changes in India’s healthcare policies and a maturing regulatory

environment have significantly brought down the risk of shifting more clinical

research from the developed countries to India. The clinical research industry in

India is presently estimated at over US$ 100 million.

New product launches underlie market growth

The market has been growing between 6-8 per cent over the last two years,

primarily driven by new launches and to some extent by volumes. In the last two

years, more than 3,900 new products (largely branded generics) have been launched

in India, contributing about US$ 355.6 million (million) worth of market value. While

the Indian pharma majors launched more than ten products per year, global MNCs

averaged one or two annually.

Cardiovascular Drug Market [1]

Cardiovascular Drug Recent reports on cardiovascular drugs

industry reveals that by the end of year 2010, the market for heart

patients in America will rise to 251 million with the greatest rate of

growth. The total market size of this industry is also expected to cross

US $ 116.3 billion by the end of 2010. Of the whole cardiovascular drugs market, the

anti hypertensive drugs sector is a leading segment with a total market share of

around 50%. Sanofi-Aventis, Glaxo Smithkline, Novartis and Boehringer, Cipla, are

the largest manufacturing companies of cardiovascular drugs in the global market. In

the last few decades, the scope of cardiovascular drugs has improved considerably

and innovative ways of treatment are being developed continuously. Cardiovascular

medicines are prescribed for treating and curing heart failure and hypertension. An

array of generic drugs is available in the market such as antiarrhythmic agent e.g.

adenosine, losartan, antithrombotic agents, vasoconstrictor tocainide, flecainide,

sotalol, amiodarone, diltiazem, or nitroglycerin.

MAJOR PLAYERS IN INDIAN MARKET

1) CIPLA-

a) Bulk drugs & intermediate.

b) Manufacture more than 150 bulk drugs.

c) Technology for products & process.

2) CADILA HEALTH CARE-

a) Bulk drugs & intermediate.

b) Contract research.

C) Formulations – cardiovascular, female health care.

d) Contribute to 70% of gross revenue.

3) AVENTIS HEALTH CARE

Anti-infective, cardiology, oncology, CNS, respiratory, bone & joints.

4) NICHOLAS PIRAMAL LTD.

Cardiology, thrombosis, CNS, Diabetes

Segment generates 76% of revenue.

COMPANY PROFILE...

COMPANY PROFILE [2]

About Kamron

Kamron Laboratories Ltd., has been set up in 1990 for manufacture of

pharmaceutical formulations in dosage forms like Tablets, Capsules, Liquid Orals,

Dry Syrups, Eye Drops and Injections.

Kamron’s manufacturing facilities are located at Rakanpur which is at a

distance of 8 kilometers from city limits of ahmedabad town. Ahmedabad is the

largest town of Gujarat state in India and is well connected by direct international

flights to Europe, USA, Middle East and Far East.

Kamron has tied up with distributors/promoters in several countries for

marketing its products in the international market. Kamron has a defined objective of

supplying its products throughout the world from its manufacturing location at

Rakanpur.

The promoter and chairman cum managing director of kamron laboratories ltd.

is Mr. kamlesh j. Laskari who is an M.B.A. and has traveled widely across the world.

He is having more than 25 years experience in the pharmaceutical field. He is assisted

by a team of well qualified, trained and experienced functional heads. The job

functions and responsibilities are well defined and there is an organization chart of the

management.

Core Values of Kamron Laboratories Ltd

We put our employees first - all the time and act in the interests of enhancing

their career progress.

We respect the personality, talent, and teamwork of all members, and value a

corporate culture that is free, energetic and dynamic.

Our customers – doctors and retailers are as important to us as our employees

and we strive our utmost every day to be a company essential to our

customers.

We shall be known as a company that meets the needs of our customers by

listening, communicating, cooperating and collaborating with our partners –

our customers.

We remain focused on the customer, committed to exceeding regulatory and

quality requirements through motivated, empowered and dedicated employees.

We observe laws and ethics, and strive to grow in harmony with society and

for the benefit of its development.

Vision statement of Kamron

“The vision of Kamron is to rank amongst the first three companies in the states

where we operate - within the next ten years. By transmitting this vision at every level

of Kamron we shall be recognized by our employees, doctors and retailers as the best

pharmaceutical company in India”.

We shall achieve this by:

Making trust, quality, integrity and excellence hallmarks of the way we conduct

our business.

Attracting, developing, motivating and retaining our talent.

Continually growing and improving our business.

Demonstrating effectiveness in how we use our resources and make business

decisions.

By implementing our strategy “Operation Trishul” to perfection so that we

become a Rs. 50 crore company by 2014.

Mission statement – Kamron

“Our mission is to become a strong regional player in the states where we

operate. We will build strong brands and be amongst the top three brands in the

segments and in the states where we operate. Our focus will be on prescription

generation so that we become a healthy organization. Honesty & integrity will be the

most important personality of Kamron”.

Facilities

Kamron has got facilities to manufacture Solid Dosage Forms. Liquid Orals

and Small Volume Parenterals.

Manufacture is carried out as per current good manufacturing practices using

state of art automatic machines. Detailed validation is carried out for each machine.

The manufacturing process is also validated so as to ensure consistent quality.

Research & Development

Kamron has got a well equipped lab wherein process R & D is carried out.

Some of the work being done include.

1. Taste Masking

2. Development of Sustained Release Products

3. Aqueous Coating and Aromatic Coating

4. Product Stability

Kamron is the first company in India to launch ciprofloxacin dispersible

tablets the technology for which was developed in house by using taste masking.

Process R & D is a continuous exercise. Several foul smelling products have

been made good smelling by use of aqueous and aromatic coating technology.

Quality Assurance

Kamron Laboratories Ltd. is committed.

To provide best quality of medicine & service to our patient for better quality

of life so as to ensure customers satisfaction.

To improve quality of our products in our pharmaceutical business by use of

latest technologies automated process & properly trained & qualified man

power.

To follow national & international standard for continual improvement in

quality management system.

International Certifications

Kamron has got several international certifications which are a testimony to

the above policy. Kamron has got:

World Health Organization – Good manufacturing practice certificate obtained

in Decemeber-2004

ISO-9001-2000 Certification from BVQI obtained in October 2005.

Brand Management Team

They have divided our products in three different groups as follows.

1) Panchratna Brands

2) Platinum Blue Group

3) Platinum Green

4) Titanium Brands: Any of the new brand will be considered under Titanium

Group

Panchratna Brands Platinum Blue Platinum Green Titanium Brands

(New Introduction)

Serra Group Allorgic Group Zidon Group Facitab IV Inj.

Lycofeast Group Azikam group Apin PM Nexa MF Tab

Marin Group Feast Feprovit Syrup Gudgut Cap / Sachet

Racifree / Rito Group Ambrokam T QXL group Lolip 10 (Atorvastatin)

Arthigo G Onkam group Kamipril 2.5 & 5 (Ramipril)

Sylron TX TNN group Thyrofeast (L-Tyrosine with

Multivitamines)

LXL 500 Vomsafe group Any of the new brand will be

considered under Titanium

Group

Brokam Syp

[Table no-2]

Product list

PROTEOLYTIC ANTI – EMETIC

Serra-5/10/20 Tab.

Serratiopeptidase 5/10/20 mg.

Serra-D Tab.

Serratiopeptidase 10 mg.

Diclofenac

Potassium 50 mg.

Serra-N Tab.

Serratiopeptidase 15 mg.

Nimesulide 100 mg.

Serra-DP Tab.

Serratiopeptidase 10 mg.

Diclofenac Sodium 50 mg.

Paracetamol 500 mg.

Serra-A Tab.

Serratiopeptidase 15 mg.

Aceclofenac 100 mg.

Zidon-DT Tab.

Domperidone Disp.

Scored 10 mg.

Onkam-4/8 Tab.

Ondansetron 4/8 mg.

Onkam-2/4 Inj.

Ondansetron 2 mg./2 ml.//4 mg./4

ml.

Onkam 30 ml. Syp.

Ondansetron 2 mg. / 5 ml.

Vomsafe Tab.

Doxylamine Succinate 10 mg.

Pyridoxine HCL 10 mg.

Vomsafe Plus Tab.

Doxylamine Succinate 10 mg.

Pyridoxine HCL 10 mg.

Folic Acid 2.5 mg.

Vomsafe OD Tab.

Doxylamine Succinate 20 mg.

Pyridoxine HCL 20 mg.

GASTRO INTENSTINAL ANTIBIOTICS

Kamtac-150 Tab.

Ranitidine 150 mg.

Omebloc Cap.

Omeprazole 20 mg.

Zidon-O Cap.

Amiron-100/250/500 Inj.

Amikacin 100 mg./250 mg./500 mg./2 ml.

inj.

Azikam Tab.

Azithromycin 250/500 mg.

Domperidone 10 mg.

Omeprazole 10 mg.

Zidon-RD Cap.

Domperidone 10 mg.

Omeprazole 20 mg.

Zidon-P Tab.

Pantoprazole 20 mg.

Domperidone 10 mg.

Zidon-PZ Tab.

Pantoprazole 40 mg.

Domperidone 10 mg.

Zidon Plus Tab

Domperidone 10 mg.

Paracetamol 500 mg.

ANTI-COUGH ANTISTAMINIC

ANTI-COLD

Brokam 100 ml. Syp.

Tebrutaline Sulphate 2.5 mg. +

Bromhexine HCL 8 mg. +

Guaiphenesin 100 mg. + Menthol 5

mg./10 ml.

Ambrokam 100 ml. Syp.

Ambroxol HCI 30 mg. + Salbutamol 2

mg. + Guaiphenesin 50 mg. /5 ml.

Ambrokam-P 60 ml.

Ambroxol HCI 15 mg. + Salbutamol

1mg. + Guaiphenesin 50 mg. + Menthol

1 mg./5 ml.

Ekocet-DT Tab.

Linkam Inj.

Lincomycin 300 mg./ml Inj. 1 ml./2 ml.

Linkam-500 Cap.

Lincomycin 500 mg.

Live-OD Tab.

Levofloxacin 200 mg.

QXL-200 Tab.

Ofloxacin 200 mg.

QXL-TZ Tab.

Ofloxacin 200 mg.

Tinidazole 600 mg.

Q-Bid-250/500 Tab.

Ciprofloxacin 250 mg./500

mg.

Q-Bid-TZ Tab.

Ciprofloxacin 500 mg.

Tinidazole 600 mg.

Roxilide-Kid Tab.

Roxithromycin

Dispersible 50 mg. Kid

Roxilide-150 Tab.

Roxithromycin 150 mg.

Sulcef Inj.

Cefoperazone 1 gm.

Sulbactum 1 gm./2 ml. Vial

Xyclox-LB Cap.

Amoxycillin 250 mg.

Cloxacillin 250 mg.

Lactic Acid Bacillus 60 Million

Spores

Cetirizine

Dihydrochloride

Disp.

10 mg.

Kamolate Tab.

Phenylephrine HCL 5 mg. + CP

Maleate 2 mg. + Caffeine 15 mg. +

Paracetamol 500 mg.

Colstat 60 ml. Syp.

Paracetamol 125 mg. +

Pseudoephedrine 15 mg. +

Chlorpheniramine Maleate 2 mg./5 ml.

Voltriz-5 Tab.

Levocetirizine 5 mg.

NUTRITIONALS

Feast Tab.

Vit. A (As acetate) 5000 i.u. + Vit. E

(As acetate) 25 i.u. + Vit. C 100 mg. +

Vit. B1 10 mg. + Vit B2 10 mg. + Vit.

B6 3 mg. + Vit B12 5 mcg. + Folic Acid

1 mg. + Niacinamide 50 mg. + Calcium

Pantothenate 12.5 mg. + Zinc Oxide 15

mg. + Cupric Oxide 2.5 mg. + Sodium

Selenate 60 mcg. + Mag. Chloride 1.4

mg. + Chromium Chloride 65 mcg.

Feprovit 200 ml. Syp.

Protein Hydrolysate 0.5 gm. +

Riboflavin 2.5 mg. + Phridoxine HCL 1

mg. + Cyanocobalamine 2.5 mcg. +

Folic Acid 0.5 mg. + Niacinamide 25

mg. + D-Panthenol 2.5 mg. + Ferros

DIGESTIVE ENZYME

Kamozyme 15 ml. Drops

Fungal Diastase (1:1200) 33.3 mg.

Pepsine (1:3000) 5 mg./1 ml.

Kamozyme 200 ml. Syp.

Fungal Diastase (1:1200) 50 mg.

Pepsine (1:3000) 10 mg./5 ml.

Kamozyme-EP Tab.

Pancreatin 192 mg.

Bile Constituents 25 mg.

Activated Dimethicone 40 mg.

ANTI - MALARIAL

Kay-Mal Inj.

œ - ß Arteether 150 mg./2 ml.

Mefkam -Q Tab.

Mefloquine 100 mg.

ANTI-GOUT

Allgoric Tab.

Allopurinol 100 mg.

ANALGESIC ANTI -

INFLAMMATORY

Tramace 1/2 ml. Inj.

Tramadol HCL 50 mg./1 ml. 100 mg./2

ml

Tramace-50 DT Tab.

Tramadol HCL 50 mg.

Gluconate 100 mg. + Calcium

Gluconate 100 mg./15 ml

Marin Cap.

Silymarin 70 mg. + Vit. B1 5 mg.+ Vit

B2 5 mg. + Vit B6 1.5 mg. + Vit. B12 5

mcg. + Niacinamide 25 mg. + Cal.

Pantothenate 7.5 mb.

Marin 100 ml. Susp.

Silymarin 35 mg. + Thiamine HCI 1.5

mg. + Riboflavin 1.5 mg. + Phridoxine

HCI 1.5 mg. + Niacinamide 20 mg. +

D-Panthenol 5 mg. + Vitamin B12 1

mcg

Marin Forte Tab.

Silymarin 140 mg. + Thiamine

Mononitrate 5 mg. + Riboflavin 5 mg. +

Pyridoxine HCI 1.5 mg. + Niacinamide

25 mg. + Calcium Pantothenate 7.5 mg.

+ Vitamin B12 5 mcg.

Mekam Tab.

Mecobalamin 500 mcg. + Thiamine

Mononitrate 10 mg. + Pyridoxine HCI 3

mg. + Niacinamide 45 mg.+ Calcium

Panthothenate 50 mg.

Mekam Inj.

Mecobalamin 1000 mcg. + Thiamine

HCI 100 mg. + Pyridoxine HCI 100 mg.

+ Niacinamide 100 mg. + D-Panthenol

50 mg./2 ml.

Mekam-DM Tab.

Mecobalamin 500 mcg. + Alpha Lipoic

Dicron-C Tab.

Diclofenac Potassium 50 mg.

Paracetamol 325 mg.

Chlorzoxazone 250 mg.

Dicron 3 ml. Inj.

Diclofenac Sodium 25 mg./ml.

Docron- SR Tab.

Diclofenac Sodium 100 mg.

Nikam Tab.

Nmesulide 100 mg

ANTI - PYRETIC

TNN Tab.

Nimesulide 100 mg.

paracetamol 500 mg.

TNN 60 ml. Susp.

Nimesulide 10 mg.

paracetamol 125 mg. / 5 ml

CALCIUM SUPPLEMENTS

Tufcal-Forte Tab.

MCHC eq. to Calcium 198 mg. +

Phosphorus 90 mg. + Zinc Sulphate 20

mg.

Tufcal 200 ml. Susp.

MCHC eq. to Calcium 99 mg. +

Phosphorous 45 mg. + Zinc Sulphat 20

mg. + Lysine Mono HCL 150 mg./10 ml.

Tufcal -M Tab.

Acid 100 mg. + Folic Acid 1.5 mg. +

Vit. B6 6 mg. + Vit. B1 10 mg. + Vit. E

25 i.u.

MV-12 Inj.

Part-I : Vitamin C 150 mg.

Part-II : Vitamin B12 2500 mcg. + Folic

Acid 0.7 mg. + Niacinamide 12 mg.

ANTI - SPASMODIC

Kamspas -250/500 Tab.

Mefenamic Acid 250/500 mg.

Dicyclomine 10 mg/20 mg.

Kamspas-T Tab.

Mefenamic 250 mg.

Tranexamic Acid 500 mg.

Draw Inj.

Drotaverine 40 mg./2 ml

HAEMATINIC

Facicap-CI Cap.

Carbonil Iron (Eq. to ele. Iron) 100 mg.

+ Folic Acid 1.5 mg. + Vit. B12 15

mcg. + Vit. C 75 mg. + Zinc Sulphate

61.8 mg.

Facicap 200 ml. Liq.

Each 15 ml. Contains:

Ferrous Gulconate 300mg. + Vit. B12

15 mcg. + Niacinamide 45 mg. +

Riboflavin 5 mg.+ Vit. B1 5 mg. + Vit.

B6 1.5 mg.

Facicap-Z Cap.

Ele. Calcium 500 mg. + vit. D3 250 I.U. +

Magnesium (Elemental) 40 mg. +

Manganese (Elemental) 1.8 mg. + Zince

Sulphate 7.5 mg. + Copper Sulphate 1

mg. Boron 250 mcg.

HAEMOSTATIC

Sylron-250/500 Tab.

Etamsylate 250/500 mg.

Sylron 2 ml. Inj.

Etamsylate 125 mg./1 ml.

Sylron-T Tab.

Tranexamic Acid 250 mg + Etamsylate

250 mg

Kool Cap.

Calcium Dobesilate 500 mg.

OTHERS

Alzomax- 25/50 Tab.

Alprazolam 0.25/0.50 mg.

Fluron-10 Tab.

Flunarizine with Beta

Cyclodextrine 10 mg.

Utegest Inj.

Natural Micronized

Progesterone

50 mg./1 ml.

200 mg./4 ml.

Utegest 20/100/200 mg. Cap.

Natural Micronized Progesterone

20/100/200 mg.

Deca-Kamolin Inj.

Ferrous Fumarate 152 mg. + Zinc

Sulphate 15 mg. + Vit. B12 mcg. +

Folic Acid 1.5 mg.

Nandrone Deconate 50 mg./ml.

Riten Tab.

Ritodrine Hydrochloride 10 mg.

Riten Inj.

Ritodrine Hydrochloride 10 mg./ml.

DATA ANALYSIS

(A) OBJECTIVES

As a student my objective was to acquire practical knowledge of marketing

field and to know the relation between theoretical and practical concepts. Moreover to

be familiar with corporate world.

From the company’s point of view my objectives were:

1. Perform a market research to determine market share of given

Molecule- Ramipril and Ramipril Hydrochlorothiazide

2. To seek the major prescribers of these molecules for the given molecule.

3. To know the market value of the given molecule before the launching of this

new molecule.

4. To know what are the regular sale and new prescription wise sale.

(B) RESEARCH METHODOLOGY:

The research began with the distribution of the allotted area into small parts.

Then the survey of 150 chemists was conducted. In that survey it was tried to seek

out maximum information from chemists related to molecule and to get information

related to status the different brands.

At the same time, prescribers of these molecules were known from the

chemists and their medical specialties were known, so that the detailed and in depth

analysis could be carried out. During the study it was also taken care to find out

market share of different brands, their pricing strategy and tried to understand their

marketing strategies, so as to implement them to increase our market share.

WORKING AREA:

I had been given the following area for the survey of all the chemists underlying in

these areas.

1. Specific area-

i. Chandkheda

ii. Sabarmati

iii. Vadaj

iv. Ranip

2. Common area-

i. VS Hospital

ii. Doctor house

iii. Stadium area

RESEARCH DESIGN:

The tool used for conducting survey is questionnaire which shown in

appendix. The questionnaire is simple and contains open ended question. It is

designed such that it can be easily understood by the respondent.

(C) PLAN OF WORK:

1-6-2010- Reporting day in the company

On that day I got some idea about how to conduct the survey and what to do during

survey, how to report.

2-6-2010 to 3-6-2010-Pilot survey

My work was started with pilot survey conducted in Ahmedabad region. In pilot

survey my objective was to know brand names of different companies and their

prices.

4-6-2010- Reporting to the company about work.

On that day I have learnt about questionnaire designing.

7-6-2010 to 22-6-2010- Survey

In these days I have surveyed different area allotted to me by the company. Actual

data collection is done during these days. I have covered all the area allotted to me.

During these days I have also reported to the company about my completed work on

alternate day.

23-6-2010 to14-7-2010- Preparation of report

During these days I have done my data analysis and prepare my report. I have search

for the molecule information, latest market etc.

15-7-2010- Submission of report in the college

(D)ABOUT THE MOLECULES

Ramipril [3] [4] [5]

Ramipril is in a group of drugs called ACE inhibitors. ACE stands for

angiotensin converting enzyme.

Ramipril is used to treat high blood pressure (hypertension), heart failure, and

to improve survival after a heart attack.

[3]

Ramipril is a potent and long-acting inhibitor of the angiotensin

convertingenzyme (ACE). It is a prodrug, which is hydrolyzed in the liver after

absorption from the gastro-intestinal tract to form the active angiotensin converting

enzyme inhibitor, ramiprilat. Hydrochlorothiazide (HCTZ) is a thiazide diuretic and

an antihypertensive. The components have quite different but complementary

antihypertensive mechanisms, and the improved efficacy is not due simply to additive

antihypertensive effects. Ramipril blocks the counterregulatory rise in angiotensin II

triggered by diuretic therapy. Diuretics appear to enhance the antihypertensive action

of ACE inhibitors particularly when the renin-angiotensin system is inactive. As a

result, patients who do not respond to monotherapy often do respond to combination

therapy. A further benefit is that the dosages of components in a combination can be

lowered for some patients, thus reducing the risk of adverse effects. Ramipril as well

as its metabolite ramiprilat has been shown to be pharmacokinetically compatible

with hydrochlorothiazide, they both require once daily dosage and achieve maximum

hypotensive effect approximately 4 hours after administration.

CLINICAL PHARMACOLOGY

Ramipril

Following oral administration of Ramipril, peak plasma concentrations of

Ramipril are reached within one hour. The extent of absorption is at least 50-60% and

is not significantly influenced by the presence of food in the GI tract, although the

rate of absorption is reduced. Cleavage of the ester group (primarily in the liver)

converts Ramipril to its active diacid metabolite, ramiprilat. Peak plasma

concentrations of ramiprilat are reached 2-4 hours after drug intake. The serum

protein binding of Ramipril is about 73% and that of ramiprilat about 56%. Ramipril

is almost completely metabolized to ramiprilat, which has about 6 times the ACE

inhibitory activity of Ramipril. After oral administration of Ramipril, about 60% of

the parent drug and its metabolites are eliminated in the urine, and about 40% is found

in the faeces. Less than 2% of the administered dose is recovered in urine as

unchanged Ramipril. Blood concentrations of Ramipril and ramiprilat increase with

increased dose, but are not strictly dose-proportional. The 24-hour AUC for

ramiprilat, however, is dose-proportional over the 2.5-20 mg dose range. The absolute

bioavailabilities of Ramipril and ramiprilat were 28% and 44%, respectively, when 5

mg of oral Ramipril was compared with the same dose of Ramipril given

intravenously. The initial rapid decline of Ramipril due to tissue distribution has a

half-life of 2-4 hours. The apparent elimination phase has a half-life of 9-18 hours.

The terminal elimination phase has a prolonged half-life (>50 hours). It does not

contribute to the accumulation of the drug. After multiple daily doses of Ramipril 5-

10 mg, the half-life of ramiprilat concentrations within the therapeutic range was 13-

17 hours. After once-daily dosing, steady-state plasma concentrations of ramiprilat are

reached by the fourth dose. Steady-state concentrations of ramiprilat are somewhat

higher than those seen after the first dose of Ramipril, especially at low doses (2.5

mg), but the difference is clinically insignificant. In patients with creatinine clearance

less than 40 ml/min/1.73m2, peak levels of ramiprilat are approximately doubled, and

trough levels may be as much as quintupled. In multiple-dose regimens, the total

exposure to ramiprilat (AUC) in these patients is 3-4 times as large as it is in patients

with normal renal function who receive similar doses. The urinary excretion of

Ramipril, ramiprilat, and their metabolites is reduced in patients with impaired renal

function. Compared to normal subjects, patients with creatinine clearance less than 40

ml/min/1.73m2 had higher peak and trough ramiprilat levels and slightly longer times

to peak concentrations. In patients with impaired liver function, the metabolism of

Ramipril to ramiprilat appears to be slowed, and plasma Ramipril levels in these

patients are increased about 3-fold. Peak concentrations of ramiprilat in these patients,

however, are not different from those seen in subjects with normal hepatic function,

and the effect of a given dose of plasma ACE activity does not vary with hepatic

function.

Hydrochlorothiazide

Thiazides affect the renal tubular mechanism of electrolyte reabsorption. Thiazides

increase excretion of sodium and chloride in approximately equivalent amounts.

Natriuresis causes a secondary loss of potassium. The mechanism of the

antihypertensive effect of thiazides is unknown. Thiazides do not affect normal blood

pressure. The onset of action of thiazides occurs in 2 hours and the peak effect at

about 4 hours. The action persists for approximately 6-12 hours. Hydrochlorothiazide

is rapidly absorbed, as indicated by peak plasma concentrations 1-2.5 hours after oral

administration. Plasma levels of the drug are proportional to dose; the concentration

in whole blood is 1.6-1.8 times higher than in plasma. Thiazides are eliminated

rapidly by the kidney. After oral administration of 12.5 to 100mg doses, 72-97% of

the dose is excreted in the urine, indicating dose independent absorption.

Hydrochlorothiazide is eliminated from plasma in a biphasic fashion with a terminal

half-life of 10-17 hours. Plasma protein binding is 67.9%. Plasma clearance is 15.9-

30.0 L/hr; volume of distribution is 3.6-7.8 L/kg. Gastrointestinal absorption of

hydrochlorothiazide is enhanced when administered with food. Absorption is

decreased in patients with congestive heart failure, and the pharmacokinetics are

considerably different in these patients.

INDICATION

Indicated for the treatment of mild to moderate hypertension in patients (in whom

combination therapy is appropriate) who have been stabilised on the individual

components given in the same proportion.

CONTRAINDICATIONS

Ramipril or Ramipril + Hydrochlorothiazide must not be used in patients with

hypersensitivity to Ramipril, hydrochlorothiazide or other thiazide diuretics,

sulphonamides or any of the excepients and allergy to starch. History of hereditary

angioneurotic oedema.Severe impairment of renal function with a creatinine clearance

below 30ml/min/1.73m2 body surface area and in dialysis patients

(hydrochlorothiazide ineffective). Haemodynamically relevant unilateral or bilateral

renal artery stenosis, mitral stenosis, aortic stenosis, and in patients with low blood

pressure (hypotensive patients) or in patients with an unstable circulatory situation

(haemodynamically unstable patients) where there might be a risk of life threatening

fall in blood pressure and renal failure. Clinically relevant electrolyte disturbances e.g.

hypokalemia, hyponatremia or hypercalcemia which may worsen following treatment.

Severe impairment of liver function (risk of fluid and salt imbalance).Rapid onset

allergy (anaphylactoid) like hypersensitivity reactions sometimes progressing to shock

have been described in the course of dialysis with certain high flux membrane

(polycrilonitril membranes) during therapy with ACE inhibitors such as Ramipril.

Pregnancy & Lactation

Ramipril or Ramipril + Hydrochlorothiazide should not be used in pregnancy as it

affects development of the foetus. If the patient becomes pregnant during treatment,

Ramipril or Ramipril + Hydrochlorothiazide mg must be replaced at the earliest with

some other group of antihypertensive agents. If treatment with Ramipril or Ramipril +

Hydrochlorothiazide is necessary during the lactation period, the infant should not be

breastfed.

PRECAUTIONS

Treatment with Ramipril or Ramipril + Hydrochlorothiazide requires regular medical

supervision. Generally dehydration, reduced blood volume (hypovolumia) or salt

depletion should be corrected before initiating the treatment (in patients with

concomitant heart failure, however, this must be carefully weighed against the risk of

volume overload). Special caution is necessary during the treatment of:

Patients with severe and particularly with malignant hypertension. Patients with

concomitant and particularly with severe heart failure. Patients in whom fluid or salt

deficiency exists or may develop (as a result of inadequate fluid or salt intake) or as a

result of diarrhoea, vomiting or excessive sweating in cases where salt and fluid

replacement is inadequate. Patients with haemodynamically relevant renal artery

stenosis. Close medical supervision is also necessary in patients with

haemodynamically relevant stenosis of coronary arteries or of the blood vessels

supplying the brain.In patients with pre-existing impairment of renal function or in

kidney transplant patients. Serum sodium, potassium, calcium, uric acid, and blood

sugar should be monitored regularly. More frequent monitoring of potassium is

necessary in patients with impaired renal function. White blood cell count should be

monitored (more frequent in the initial phase of the treatment) so that leucopenia can

be detected.

ADVERSE REACTIONS

The following adverse effects can be observed during therapy with

Cardiovascular

Symptomatic hypotension characterised by light-headedness sometimes accompanied

by concentration disturbances as well as impaired reactions, fatigue, dizziness,

weakness may occur as a result of vasodilatation after the initial dose of Ramipril or

Ramipril or Ramipril + Hydrochlorothiazide. Other symptoms may include

tachycardia, palpitation, orthostatic hypotension, nausea, headache, tiredness or

tinnitus after excessive reduction of blood pressure. This occurrence may be more

likely in patients with:

Severe and malignant hypertension

Concomitant and particularly severe heart failure

Previous diuretic therapy

Fluid or salt deficiency

Haemodynamically relevant renal artery stenosis.

Pre-existing coronary artery disease or cerebrovascular disease, a sudden fall

in blood pressure may cause perfusion disturbances to the heart (angina

pectoris or myocardial infarction) or the brain (transient ischemic attacks or

stroke).

Renal

During treatment with Ramipril or Ramipril + Hydrochlorothiazide there may be

deterioration in renal function under certain circumstances progressing to life-

threatening acute renal failure. This applies particularly in patients with renovascular

diseases (haemodynamically relevant renal artery stenosis, in renal transplant patients

and in patients of cardiac failure). In isolated cases, interstitial nephritis may develop

during therapy with hydrochlorothiazide. Preexisting pronounced urinary protein

excretion might increase under treatment with Ramipril or Ramipril +

Hydrochlorothiazide however renal protein excretion may also be reduced in patients

of diabetic nephropathy. Ramipril or Ramipril + Hydrochlorothiazide may lead to a

decline in serum sodium concentration particularly in conjunction with restricted salt

intake. Hydrochlorothiazide may contribute to the development of hypochloremia,

hypomagnesemia as well as hypercalcemia. In addition Ramipril or Ramipril +

Hydrochlorothiazide may contribute to development or aggravation of a metabolic

alkalosis. Ramipril may contribute to an increase in concentration of serum potassium

while hydrochlorothiazide may contribute to a decrease in serum potassium. Thus

during the therapy with Ramipril or Ramipril + Hydrochlorothiazide both a decline

and increase in serum potassium are possible, the latter effect being mainly

encountered in patients with impaired renal function (e.g. diabetic nephropathy) or

those receiving potassium sparing diuretics or potassium salts concomitantly.

Warning signs of electrolyte disturbances (e.g. changes in serum levels of sodium,

potassium, calcium and magnesium) include thirst, headache, confusion, muscle

cramps, tetany, muscle weakness and gastrointestinal symptoms.

Gastrointestinal

Reactions in digestive tract may develop e.g. dryness of mouth, irritation or

inflammation of oral mucosa, constipation, diaorrhea, nausea and vomiting, gastritis

like abdominal pain, pancreatitis, increase in hepatic enzymes and/or bilirubin,

cholestatic jaundice and other forms of impaired liver function and in some instances

life threatening hepatitis.

Blood picture

The following changes in blood picture may occur: a mild to severe reduction in red

blood cell count and haemoglobin content, blood platelets and white blood cell count,

impaired blood cell formation (bone marrow depression) and excessive reduction in

number of all blood cells (pancytopenia) have been observed. Such changes in blood

picture that are sometimes life-threatening are more likely to occur in patients of

impaired renal function, in patients with concomitant connective tissue disorder or in

patients treated with other drugs that may cause changes in blood picture.

Others

Disturbance of balance, visual disorders, headache, nervousness, restlessness, tremor,

sleep disturbances, confusion, and loss of appetite, depressed mood, feeling of

anxiety, abnormal sensations, taste change and muscle cramps. Erectile impotence

and reduced sexual desire (decreased libido) may occur. Inflammation of blood

vessels (vasculitis), muscle and joint pains (myalgia and arthralgia), fever,

eosinophilia may occur. During treatment with hydrochlorothiazide and thus, with

Ramipril or Ramipril + Hydrochlorothiazide increased blood concentrations of uric

acid levels may occur. This may lead to gout attacks particularly in those patients

whose uric acid levels are already elevated. Hydrochlorothiazide might lower the

tolerance of glucose. In patients with diabetes mellitus this may lead to deterioration

of metabolic control. A latent diabetes mellitus may become manifest for the first

time. Hydrochlorothiazide may cause an increase in serum cholesterol and

triglycerides. Raised titres of antinuclear antibodies have been seen with other ACE

inhibitors. In temporal relationship with the use of hydrochlorothiazide, the

development of lupus erythematosus has been described.

Effects on the ability to drive and operate machinery:

The antihypertensive effect in individual cases may be symptomatic. Treatment with

Ramipril or Ramipril + Hydrochlorothiazide may therefore, affect the ability to drive,

cross the road safely or operate machinery, especially at the start of treatment or when

changing over from other preparations, or during concomitant use of alcohol.

INTERACTIONS

Combination with diuretics or other antihypertensive agents or nitrates and tricyclic

antidepressants may potentiate the antihypertensive response to Ramipril or Ramipril

+ Hydrochlorothiazide. Patients previously treated with diuretics may experience a

marked drop in blood pressure. Potassium-sparing diuretics such as spironolactone,

amiloride and triamterene or potassium supplements may increase the risk of

hyperkalemia. Ramipril or Ramipril + Hydrochlorothiazide may weaken the

effectiveness of blood sugar lowering medications (antidiabetic agents, e.g. insulin

and sulphonylurea derivatives).

A high intake of dietary salt may decrease the effects of antihypertensive medication.

Leukopenia may be aggravated in patients undergoing treatment with

immunosuppressants, cytostatic agents, systemic corticosteroids or allopurinol.

Concurrant administration of methyldopa may result in hemolysis. Since ACE

inhibitors decrease the excretion of lithium salts, lithium concentrations in the blood

should be monitored in patients undergoing such therapy. When Ramipril or Ramipril

+ Hydrochlorothiazide are administered simultaneously with nonsteroidal

antihypertensive drugs (e.g. acetyl salicylic acid or indomethacin) attenuation of

antihypertensive effect and moreover acute renal failure may occur. Ramipril or

Ramipril + Hydrochlorothiazide may potentiate the effects of alcohol.

DOSAGE AND ADMINISTRATION

Hypertension:

The recommended initial dosage is 1 capsule/tablet of Ramipril or Ramipril +

Hydrochlorothiazide once a day. It is started with Ramipril alone first then if required

then with diuretics. The dose can be up titrated at intervals of 2-3 weeks to Ramipril

5mg and hydrochlorothiazide 12.5mg and then to a maximum of Ramipril 10 mg and

hydrochlorothiazide 12.5 mg. If required another antihypertensive agent may be

added. In patients pre-treated with a diuretic, consideration must be given to

discontinuing the diuretic at least 2-3 days (depending on the duration of action of the

diuretic) longer before initiating the treatment with Ramipril or Ramipril +

Hydrochlorothiazide. If discontinuation is not possible the treatment should be

initiated with the smallest possible dose of Ramipril (1.25mg daily) in a free

combination. Subsequently a changeover to an initial daily dose of Ramipril or

Ramipril + Hydrochlorothiazide not exceeding one capsule should be made.

Dosage in patients with impaired renal function:

For patients with creatinine clearance between 60 and 30ml/min/1.73m2 body surface

area, treatment is initiated with Ramipril alone 1.25mg. After gradually increasing the

dose of Ramipril, medication with Ramipril or Ramipril + Hydrochlorothiazide is

initiated at a daily dose of 1 capsule. The maximum permitted daily dose is 2 capsules

of Ramipril or Ramipril + Hydrochlorothiazide in such patients.

Administration

Generally, the prescribed daily dose should be taken in the morning as a single dose.

The capsules must be swallowed as a whole with sufficient amounts of liquid (approx

½ glass). They may be taken before during or after a meal.

DATA INTERPRETATION

(E) AVAILABLE BRANDS IN THE MARKET

BRAND NAME COMPANY NAME AVAILABLE STRENGTH

CARDACE Sanofi Aventis 2.5mg, 5mg, 2.5H, 5H

HOPACE Micro Cardicare 2.5mg, 5mg, 2.5H, 5H

RAMIPRES Cipla 2.5mg, 5mg, 2.5H

RAMACE Astra Zeneca 2.5mg, 5mg, 2.5H

RAMISTAR Lupin 2.5mg, 5mg, 2.5H, 5H

RL Sunij Pharma 2.5mg, 5mg, 2.5H

RAMCOR Epca 2.5mg, 5mg, 2.5H, 5H

RACE Alkem 2.5mg, 5mg, 2.5H

ODIPRIL Blue Cross 2.5mg, 5mg, 2.5H, 5H

MACPRIL Macleods 2.5mg, 5mg, 2.5H, 5H

ZIRAM Fdc 2.5mg, 5mg

ZOREM Intas 2.5mg, 5mg

RAMIHEART Mankind 2.5mg, 5mg

[Table no-3]

Notes: Here,

2.5 mg= 2.5 mg of Ramipril

5 mg= 5 mg of Ramipril

2.5 H= 2.5 mg of Ramipril + 12.5 mg of Hydrochlorothiazide

5 H= 5 mg of Ramipril + 12.5 mg of Hydrochlorothiazide

(F) DATA ANALYSIS

1) Sale of number of strips per week of different companies

From sale of no. of strips per week we can know what is the total

market share captured by the brands.

Brand Name Company Name Sale of strips per

week

Cardace Sanofi Aventis 391

Hopace Micro Cardicare 114

Ramipres Cipla 275

Ramace Astra Zeneca 135

Ramistar Lupin 281

Rl Sunij Pharma 215

Ramcor Epca 62

Race Alkem 70

Odipril Blue Cross 22

Macpril Macleods 250

Ziram Fdc 131

Zorem Intas 32

Ramiheart Mankind 9

Total 1987

[Table no-4]

[Graph 1]

391

114

275

135

281

215

6270

22

250

131

32

9

0

50

100

150

200

250

300

350

400

450Sa

le o

f st

rip

per

wee

k

Brand Name

Sale of number of strips per week of different companies

sale/ week

Percentage of total sale

Brand Name Sale of strips per

week

Percentage of total

sale/week

Cardace 391 19.67791

Hopace 114 5.737292

Ramipres 275 13.83996

Ramace 135 6.794162

Ramistar 281 14.14192

Rl 215 10.82033

Ramcor 62 3.120282

Race 70 3.522899

Odipril 22 1.107197

Macpril 250 12.58178

Ziram 131 6.592854

Zorem 32 1.610468

Ramiheart 9 0.452944

Total 1987 100 %

[Table no-5]

[Graph 2]

19.67

5.73

13.83

6.7914.14

10.82

3.12

3.52

1.1

12.58

6.59

1.610.45

Percentage of total sale

Cardace

Hopace

Ramipres

Ramace

Ramistar

Rl

Ramcor

Race

Odipril

Macpril

Ziram

2) Sale Of Strip Of Ramipril And Ramipril

Hydrochlorothiazide

This analysis indicates strength wise sale of given brands. That interprets

which strength of the brand sell out more. This helps in estimating which strength

prescribed more by the doctor or running more in the market.

Strength Sales Percentage of sale

2.5 mg Ramipril 1399 70.40

5 mg Ramipril 426 21.43

2.5 mg of Ramipril + 12.5 mg

hydrochlorotiazide

156 7.85

5 mg of Ramipril + 12.5 mg

hydrochlorotiazide

6 0.30

Total 1987 100

[Table no-6]

[Graph 3]

70%

22%

8%

0%

Percentage of sale(Strength Wise)

2.5

5

2.5H

5H

3) Sale Of Strip Of Ramipril And Ramipril

Hydrochlorothiazide (Dosage form wise)

By this analysis we can know that which dosage form is prefer more in

the market. It helps in determining which dosage we can launch in the market

that will succeed.

Form 2.5 5 2.5H 5H Total %

TAB 792 237 102 10 1141 88.85

CAP 187 55 8 0 250 11.15

100

[Table no-7]

[Graph 4]

88.85

11.15

Sales(Dosage Form Wise)

Tablet

Capsule

4) Unit Percentage Value

Unit percentage value is the value which gives information about

percentage of total revenue generated from sale of the brand.

It is calculated from total unit sale of the product and price per unit.

Brand

Name

Price Unit Sale Value Unit %

Sale

2.5 5 2.5H 5H 2.5 5 2.5H 5H

Cardace 6.54 10.78 6.6 11.4 2750 820 290 50 29308.6 28.57

Hopace 4.5 8 4.8 770 290 80 6169 6.01

Ramipres 4.52 7.51 4.99 1900 650 200 14467.5 14.10

Ramace 6.73 11.13 4.5 1455 420 100 14916.75 14.54

Ramistar 5.5 8.2 6.1 1860 560 380 17140 16.71

Rl 2.4 4.4 2.9 1470 480 200 6220 6.06

Ramcor 2.5 5 470 110 1901 1.85

4.4 40

Race 5.4 6.5 5.5 530 140 50 4047 3.95

Odipril 2 3 2.5 150 50 20 500 0.49

Macpril 1.1 2.2 1.75 1770 530 200 3486 3.40

Ziram 1.78 3.49 1020 290 2836.7 2.77

Zoram 5.21 8.66 270 50 1581.2 1.54

Total 102573.75 100

[Table no-8]

[Graph 5]

0

5

10

15

20

25

30

Un

it %

Val

ue

Brand Name

Unit % Value

5) Analysis of regular sale and new prescription.

In this analysis we can know regular customer and new

customer of this molecule

Table no-

Brand Name Total sale Total sale(new

prescription)

Total sale

(regular)

Cardace 391 256 135

Hopace 114 79 35

Ramipres 275 194 81

Ramace 135 95 40

Ramistar 281 183 98

Rl 215 168 47

Ramcor 62 42 20

Race 70 43 27

Odipril 22 16 6

Macpril 250 178 72

Ziram 131 95 36

Zorem 32 21 11

Ramiheart 9 9 0

Total 1987 1391 596

[Table no-9]

[Graph 6]

0

50

100

150

200

250

300

sale

Brand Name

Total sale(Regular Vs New Prescription)

Total sale(new prescription) Total sale (regular)

FINDINGS

As per the survey conducted, the market share of different companies is quite

different. Many companies are available in the market but few brands are

running good.

The market share of SANOFI AVENTIS under the brand name of CARDACE

is around 20 %. Then other brands are also having good position like

RAMISTAR (LUPIN) – 14.14%

RAMIPRES (CIPLA)- 13.83%

MACPRIL (MACLOEDS)- 12.58%

Most Prescribed strength in Ramipril is 2.5mg because the treatment is started

with normal dose. Then the doctor moves to higher dose. Based on severity

Ramipril hydrochlorothiazide is prescribed.

I also came to know that doctors are also prescribing hypertensive drugs other

than the Ramipril also.

Price difference is more among the brands. MACPRIL 2.5 mg is available

only at Rs.11 while CARDACE 2.5 mg is available at Rs. 65.

88.85 % brands are available in Tablet form while only 11.15 % brands are

available in capsule form.

All brands are available in 10 TAB/strip except RAMACE which is available

in 15 TAB/strip.

Pharmaceutical market is most dynamic and continuously changing market so

nothing is permanent.

SUGGESTIONS

I would like to give following suggestions based on my market survey,

1. Market share of CARDACE is highest though its price is high than others

because most doctors prefer more that. So company should think about this

price factor and also how to conduct doctors that they prescribe more.

2. Company should think about field force penetration in different areas in which

will help in capture the market.

3. For the help of field force I have specified name of major prescribers of each

brand so company should give more attention on them.

4. Price range is around 10-30 Rs. for lower brands and for higher brand 40-60

Rs. so keep it around 15-20 Rs.

5. Most preferred strength is 2.5 mg and 5 mg of Ramipril. Ramipril

hydrochlorothiazide is less preferred. So my suggestion is to concentrate on only

Ramipril.

6. During my survey I came to know doctors are preferred Tablet form more than

capsule so my suggestion is to keep the dosage form to Tablet form.

7. Promotional efforts are zero from the company. So we can include promotional

efforts like leaflets, posters, banners etc.

LIMITATION OF SURVEY

This survey is conducted in limited area in Ahmedabad. So it is not total

picture or reflection of the market of whole Ahmedabad. So it cannot be

generalized.

The findings in this study are purely dependent on the answers of the

respondents.

The information recorded is based on the opinion and reactions of the

respondents as on the date of research.

References

1. http://www.themedica.com/drug/cardiovascular-drug/

2. http://www.kamronlabs.in

3. http://www.drugs.com/ramipril.html

4. http://www.drugs.com/dosage/ramipril.html#ixzz0sRXmqiIk

5. http://www.drugs.com/ppa/ramipril.html#ixzz0sRWRpeFoF

APPENDIX

Questionnaire

Name of the Chemist:

Date:

Area:

1) Which brands of Ramipril and Ramipril + Hydrochlorothiazide you are

having:

Brand name Company name Dosage forms

Tablet Capsule

2) In which strength tablet and capsule are available?

Brand name Company name

Tablet

mg of Ramipril

+ mg of

hydrochlorothiazid

e

Capsule

mg of Ramipril

+ mg of

hydrochlorothiazi

de

3) Which type of packaging available for tablet & capsule?

Brand name Company name Tablet/strip or

Capsule/strip

4) What is the MRP of the brands?

Brand name Company name Rs./Tablet or Rs./Capsule

5) How much quantity of Ramipril you sell per day?

6) Approximately how much quantity of each brand you sell per day?

Brand name Company name Tablet/day or Capsule/day

7) How many no of prescription are you handling during the day from Dr.?

Brand name Doctor’s name

Prescription

strength Speciality

No of

prescriptions/

day

8) Promotional efforts made by the company:

Thank you very much.